or Try an Advanced Search...

    Technical Analysis for ARGX - argenx SE

    Grade Last Price % Change Price Change
    B 605.66 -0.04% -0.26
    ARGX closed down 0.04 percent on Monday, November 25, 2024, on 1.3 times normal volume. The bulls were able to push the stock to a new 52-week high. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
    5 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Up Up Up
    Historical ARGX trend table...
    Date Alert Name Type % Chg
    MACD Bullish Signal Line Cross Bullish 0.00%
    New 52 Week High Strength 0.00%
    Stochastic Reached Overbought Strength 0.00%
    Gapped Up Strength 0.00%
    Overbought Stochastic Strength 0.00%
    New 52 Week Closing High Bullish -0.04%
    Calm After Storm Range Contraction -0.04%
    Gapped Up Strength -0.04%
    Up 3 Days in a Row Strength -0.04%
    Up 4 Days in a Row Strength -0.04%
    Older End-of-Day Signals for ARGX ...

       Recent Intraday Alerts

    Alert Time
    60 Minute Opening Range Breakdown about 19 hours ago
    Possible NR7 about 19 hours ago
    2x Volume Pace about 22 hours ago
    Up 2% about 23 hours ago
    Upper Bollinger Band Resistance about 23 hours ago
    View Earlier Intraday Alerts

    Get a Trading Sidekick!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators
    ARGX Chart by TradingView
    Basic chart:

    Profile

    argenx SE Description

    argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company’s lead clinical stage product candidates include ARGX-113, a product in Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis and immune thrombocytopenia; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of hematological cancers, such as T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome. It is also developing ARGX-111 to treat solid tumors with MET amplification; ARGX-109 for the treatment of rheumatoid arthritis; ARGX-112 to treat skin inflammation; ARGX-115, a cancer immunotherapy-focused product candidate; and ARGX-116 for the treatment of dyslipidemia. The company has license and collaboration agreements with AbbVie S.Á.R.L.; Bird Rock Bio, Inc.; LEO Pharma A/S; Shire International GmbH; and Bayer AG. argenx SE was founded in 2008 and is based in Breda, the Netherlands.

    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biopharmaceutical Cancer Solid Tumors Immunotherapy Autoimmune Disease Cancer Immunotherapy Inflammation Acute Myeloid Leukemia Lymphoma Rheumatoid Arthritis Lipid Myelodysplastic Syndrome Treatment Of Autoimmune Disease Myasthenia Gravis Dyslipidemia Hematological Cancers Myasthenia Thrombocytopenia Skin Inflammation Janus Kinase Inhibitor Rgx Therapies For The Treatment Of Autoimmune Diseases Treatment Of Hematological Cancers

    Is ARGX a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Nov 22 Halozyme drops Evotec buyout bid; Patient dies in Neurogene trial
    Nov 20 argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory Myopathies
    Nov 18 Is argenx SE (ARGX) the Best Immunotherapy Stock to Buy Now?
    Nov 14 (ARGX) - Analyzing argenx's Short Interest
    Nov 12 Argenx upgraded at Wolfe on myasthenia gravis dominance
    Nov 11 Zai Lab and argenx Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China
    Nov 11 argenx and Zai Lab Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy in China
    Nov 6 Peering Into argenx's Recent Short Interest
    Nov 5 Why Argenx (ARGX) Might be Well Poised for a Surge
    Nov 5 argenx to Participate at Upcoming Investor Conferences
    See more ARGX news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 618.4
    52 Week Low 327.73
    Average Volume 240,045
    200-Day Moving Average 459.82
    50-Day Moving Average 559.01
    20-Day Moving Average 586.91
    10-Day Moving Average 589.51
    Average True Range 15.02
    RSI (14) 62.26
    ADX 29.36
    +DI 37.85
    -DI 16.04
    Chandelier Exit (Long, 3 ATRs) 573.33
    Chandelier Exit (Short, 3 ATRs) 590.62
    Upper Bollinger Bands 618.41
    Lower Bollinger Band 555.40
    Percent B (%b) 0.8
    BandWidth 10.74
    MACD Line 10.73
    MACD Signal Line 10.50
    MACD Histogram 0.2272
    Fundamentals Value
    Market Cap 35.85 Billion
    Num Shares 59.2 Million
    EPS -4.10
    Price-to-Earnings (P/E) Ratio -147.72
    Price-to-Sales 23.10
    Price-to-Book 8.32
    PEG Ratio 0.00
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 625.28
    Resistance 3 (R3) 627.35 622.87 622.01
    Resistance 2 (R2) 622.87 617.88 621.84 620.92
    Resistance 1 (R1) 614.27 614.79 612.03 612.20 619.83
    Pivot Point 609.79 609.79 608.68 608.76 609.79
    Support 1 (S1) 601.19 604.80 598.95 599.12 591.49
    Support 2 (S2) 596.71 601.71 595.68 590.40
    Support 3 (S3) 588.11 596.71 589.31
    Support 4 (S4) 586.04